Here is just a brief introduction to this compound(56621-48-8)HPLC of Formula: 56621-48-8, more information about the compound(4-(Piperazin-1-yl)phenol) is in the article, you can click the link below.
Most of the compounds have physiologically active properties, and their biological properties are often attributed to the heteroatoms contained in their molecules, and most of these heteroatoms also appear in cyclic structures. A Journal, Article, Research Support, Non-U.S. Gov’t, Research Support, N.I.H., Extramural, ACS Chemical Biology called Molecular Mechanism for Isoform-Selective Inhibition of Acyl Protein Thioesterases 1 and 2 (APT1 and APT2), Author is Won, Sang Joon; Davda, Dahvid; Labby, Kristin J.; Hwang, Sin Ye; Pricer, Rachel; Majmudar, Jaimeen D.; Armacost, Kira A.; Rodriguez, Laura A.; Rodriguez, Christina L.; Chong, Fei San; Torossian, Kristopher A.; Palakurthi, Jasmine; Hur, Edward S.; Meagher, Jennifer L.; Brooks, Charles L.; Stuckey, Jeanne A.; Martin, Brent R., which mentions a compound: 56621-48-8, SMILESS is OC1=CC=C(N2CCNCC2)C=C1, Molecular C10H14N2O, HPLC of Formula: 56621-48-8.
Post-translational S-palmitoylation directs the trafficking and membrane localization of hundreds of cellular proteins, often involving a coordinated palmitoylation cycle that requires both protein acyltransferases (PATs) and acylprotein thioesterases (APTs) to actively redistribute S-palmitoylated proteins toward different cellular membrane compartments. This process is necessary for the trafficking and oncogenic signaling of S-palmitoylated Ras isoforms, and potentially other peripheral membrane proteins. Depalmitoylating enzymes APT1 and APT2 are sep. conserved in all vertebrates, suggesting unique functional roles for each enzyme. The recent discovery of APT isoform-selective inhibitors ML348 and ML349 has opened new possibilities to probe the function of each enzyme, yet it remains unclear how each inhibitor achieves orthogonal inhibition. Here, the authors report the high-resolution structure of human APT2 in complex with ML349 (1.64 Å), as well as the complementary structure of human APT1 bound to ML348 (1.55 Å). Although the overall peptide backbone structures are nearly identical, each inhibitor adopted a distinct conformation within each active site. In APT1, ML348 was positioned above the catalytic triad, but in APT2, the sulfonyl group of ML349 formed H-bonds with active site resident water mols. to indirectly engage the catalytic triad and oxyanion hole. Reciprocal mutagenesis and activity profiling revealed several differing residues surrounding the active site that served as critical gatekeepers for isoform accessibility and dynamics. Structural and biochem. anal. suggested that the inhibitors occupy a putative acyl-binding region, establishing the mechanism for isoform-specific inhibition, hydrolysis of acyl substrates, and structural orthogonality important for future probe development.
Here is just a brief introduction to this compound(56621-48-8)HPLC of Formula: 56621-48-8, more information about the compound(4-(Piperazin-1-yl)phenol) is in the article, you can click the link below.
Reference:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem